Cargando…

Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example

Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and...

Descripción completa

Detalles Bibliográficos
Autor principal: Maguire, Greg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196663/
https://www.ncbi.nlm.nih.gov/pubmed/35240929
http://dx.doi.org/10.1080/21645515.2022.2043105
_version_ 1784727244509282304
author Maguire, Greg
author_facet Maguire, Greg
author_sort Maguire, Greg
collection PubMed
description Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and dosing strategy to induce “physiological renormalization” to induce mimicry in the innate and adaptive immune systems in the respiratory tracts and sera, similar to that when the body encounters the natural infectious agent.
format Online
Article
Text
id pubmed-9196663
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91966632022-06-15 Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example Maguire, Greg Hum Vaccin Immunother Coronavirus – Commentary Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and dosing strategy to induce “physiological renormalization” to induce mimicry in the innate and adaptive immune systems in the respiratory tracts and sera, similar to that when the body encounters the natural infectious agent. Taylor & Francis 2022-03-03 /pmc/articles/PMC9196663/ /pubmed/35240929 http://dx.doi.org/10.1080/21645515.2022.2043105 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Coronavirus – Commentary
Maguire, Greg
Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
title Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
title_full Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
title_fullStr Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
title_full_unstemmed Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
title_short Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
title_sort using a “systems therapeutic for physiological renormalization” approach to vaccine development. covid-19 as an example
topic Coronavirus – Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196663/
https://www.ncbi.nlm.nih.gov/pubmed/35240929
http://dx.doi.org/10.1080/21645515.2022.2043105
work_keys_str_mv AT maguiregreg usingasystemstherapeuticforphysiologicalrenormalizationapproachtovaccinedevelopmentcovid19asanexample